DocMorris on the Rise: How Online Pharmacies Are Conquering Germany

Introduction: Growth That Surprised the Market

Wednesday was a triumphant day for the Swiss online pharmacy and telemedicine group DocMorris 0RRB.L ... . The company’s shares jumped by approximately 7 percent after it published second-quarter results that exceeded expectations. External revenue increased by 15.2 percent in local currency, reaching CHFUSD ... CHF 309.7 million. Reported revenue rose by 16.1 percent to CHF 295.4 million.

What is behind this success? The main driver was Germany, where external revenue from prescription medicines surged by 45.8 percent. Digital services, including TeleClinic and the marketplace business, grew by 80 percent. The active customer base expanded by 1.1 million people, reaching 12.9 million.

In this article, we will examine the key factors driving DocMorris’s growth, assess its prospects, and consider whether the company will be able to reach EBITDA break-even in 2026.

Key Financial Indicators

Revenue Growth of 15.2 Percent

DocMorris’s external revenue increased by 15.2 percent in local currency to CHF 309.7 million. Reported revenue rose by 16.1 percent to CHF 295.4 million. This significant increase exceeded market expectations.

Growth was primarily driven by Germany, where external revenue from prescription medicines surged by 45.8 percent. This represented an acceleration compared with the first quarter, when growth stood at 28.6 percent.

Digital Services Grow by 80 Percent

Digital services, including TeleClinic, retail media, and the marketplace business, grew by 80 percent to CHF 13.9 million. This segment is becoming increasingly important for the company, helping to diversify its sources of revenue.

The expansion of digital services indicates that DocMorris is successfully developing an ecosystem that extends beyond the traditional online pharmacy business.

The Active Customer Base Continues to Grow

DocMorris’s active customer base increased by 1.1 million compared with the previous year, reaching 12.9 million. This growth was supported by a significant influx of new customers purchasing prescription medicines.

The expansion of the customer base creates a foundation for future growth and strengthens brand loyalty.

Germany as the Key Growth Driver

Prescription Medicine Sales Increase by 45.8 Percent

Germany became the main engine of DocMorris’s growth. External revenue from prescription medicines surged by 45.8 percent, accelerating compared with the first quarter. This impressive result reflects the strong demand for online healthcare services in the country.

The German prescription medicine market is one of the largest in Europe, and DocMorris is successfully taking advantage of this demand.

Acceleration Compared with the First Quarter

Growth in prescription medicine sales accelerated from 28.6 percent in the first quarter. This suggests that the company is gaining momentum and successfully implementing its strategy.

The acceleration may also be connected with seasonal factors or changes in consumer behavior.

Marketing Strategy

Jefferies analysts noted that “the clear acceleration compared with previous quarters shows that the more targeted use of a reduced marketing budget is paying off.” This means that DocMorris has become more efficient in the way it uses its marketing resources.

The combination of a lower marketing budget and accelerating growth indicates an improvement in operational efficiency.

Digital Services: A New Growth Driver

Growth of 80 Percent

Digital services, including TeleClinic, retail media, and the marketplace business, grew by 80 percent to CHF 13.9 million. This is the fastest-growing segment of DocMorris’s business.

TeleClinic, the company’s telemedicine service, is becoming increasingly popular, particularly amid continuing uncertainty in the healthcare sector.

Revenue Diversification

The growth of digital services is diversifying DocMorris’s sources of income and reducing its dependence on prescription medicine sales. This makes the business more resilient to changes in the market.

The marketplace and retail media businesses also create new opportunities to monetize the company’s customer base.

Growth Potential

Digital services have significant growth potential. As telemedicine and online commerce continue to develop, this segment could become even more important for DocMorris in the future.

Investments in digital services may deliver long-term returns by creating new sources of revenue.

Forecasts and Prospects

EBITDA Break-Even in 2026

DocMorris stated that the accelerating growth of prescription medicine sales means the company remains “fully on track” to achieve EBITDA break-even during 2026. This is an important signal for investors.

Reaching break-even will be a major milestone for a company that has invested heavily in growth for many years.

Updated Outlook for 2026

The company will update its full-year 2026 guidance when it publishes its half-year results on August 19. The updated forecast will include the positive impact of trading during the first half of the year and the recently announced “AI-First” strategy.

The “AI-First” strategy is expected to generate annual cost savings of at least CHF 15 million. This could significantly improve the company’s financial performance.

The “AI-First” Strategy

The introduction of artificial intelligence could improve operational efficiency, enhance customer service, and reduce costs. This is an important step for DocMorris that could provide the company with a competitive advantage.

Annual cost savings of at least CHF 15 million could make a significant contribution to achieving break-even.

What This Means for Investors

A Positive Signal

Revenue growth of 15.2 percent and the acceleration of prescription medicine sales in Germany are positive signals for investors. The company’s shares rose by 7 percent, reflecting market optimism.

Investors are likely expecting further growth and continued improvement in the company’s financial performance.

Risks and Challenges

Despite the positive results, DocMorris continues to face risks. Competition in the online pharmacy market is intensifying, while healthcare regulations may change.

The company must continue investing in growth while maintaining operational efficiency.

Long-Term Prospects

Over the long term, DocMorris has significant potential. The expansion of the online pharmacy market, the development of telemedicine, and the introduction of artificial intelligence are creating opportunities for further growth.

Investors may view DocMorris as a promising asset in the digital healthcare sector.

Conclusion: Success in Germany and New Horizons

The second quarter of 2026 was a period of impressive growth for DocMorris. External revenue increased by 15.2 percent, while prescription medicine sales in Germany surged by 45.8 percent. Digital services grew by 80 percent, helping to diversify the company’s revenue.

The active customer base expanded by 1.1 million people to 12.9 million. This creates a strong foundation for future growth and strengthens customer loyalty to the brand.

DocMorris confirmed its plans to achieve EBITDA break-even in 2026 and announced an “AI-First” strategy expected to generate annual cost savings of at least CHF 15 million.

For investors, DocMorris’s results represent a positive signal. The company’s shares rose by 7 percent, reflecting market optimism. However, risks remain, including increasing competition and potential regulatory changes.

DocMorris continues to develop by taking advantage of opportunities in digital healthcare and artificial intelligence. The coming months will show whether the company can maintain its growth momentum and reach break-even.